Bio-Path Holdings, Inc. (BPTH)
USD 0.15
(0.0%)
USD 0.15
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.77 Million USD | 54.65% |
| 2022 | 1.79 Million USD | 61.75% |
| 2021 | 1.11 Million USD | -20.93% |
| 2020 | 1.4 Million USD | -10.74% |
| 2019 | 1.57 Million USD | 40.91% |
| 2018 | 1.11 Million USD | 41.21% |
| 2017 | 791 Thousand USD | -80.01% |
| 2016 | 3.95 Million USD | 322.01% |
| 2015 | 937.41 Thousand USD | 66.81% |
| 2014 | 561.97 Thousand USD | 90.56% |
| 2013 | 294.89 Thousand USD | -10.43% |
| 2012 | 329.24 Thousand USD | 4.15% |
| 2011 | 316.13 Thousand USD | 28.11% |
| 2010 | 246.75 Thousand USD | -6.85% |
| 2009 | 264.9 Thousand USD | -19.06% |
| 2008 | 327.28 Thousand USD | 72.65% |
| 2007 | 189.56 Thousand USD | -18.25% |
| 2006 | 231.87 Thousand USD | -27.31% |
| 2005 | 318.97 Thousand USD | 31.6% |
| 2004 | 242.37 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.82 Million USD | -12.88% |
| 2024 Q1 | 4.39 Million USD | 58.08% |
| 2023 Q4 | 2.77 Million USD | 11.34% |
| 2023 Q2 | 1.48 Million USD | -25.76% |
| 2023 FY | 2.77 Million USD | 54.65% |
| 2023 Q1 | 1.99 Million USD | 11.02% |
| 2023 Q3 | 2.49 Million USD | 68.53% |
| 2022 FY | 1.79 Million USD | 61.75% |
| 2022 Q3 | 2.34 Million USD | 57.29% |
| 2022 Q2 | 1.48 Million USD | -15.54% |
| 2022 Q1 | 1.76 Million USD | 58.69% |
| 2022 Q4 | 1.79 Million USD | -23.27% |
| 2021 Q2 | 1.37 Million USD | -20.45% |
| 2021 Q1 | 1.72 Million USD | 22.85% |
| 2021 FY | 1.11 Million USD | -20.93% |
| 2021 Q3 | 1.33 Million USD | -2.84% |
| 2021 Q4 | 1.11 Million USD | -16.72% |
| 2020 Q1 | 1.89 Million USD | 20.33% |
| 2020 Q2 | 1.5 Million USD | -20.33% |
| 2020 Q3 | 1.68 Million USD | 11.8% |
| 2020 Q4 | 1.4 Million USD | -16.72% |
| 2020 FY | 1.4 Million USD | -10.74% |
| 2019 Q1 | 1.17 Million USD | 5.28% |
| 2019 FY | 1.57 Million USD | 40.91% |
| 2019 Q4 | 1.57 Million USD | 0.19% |
| 2019 Q3 | 1.57 Million USD | 11.74% |
| 2019 Q2 | 1.4 Million USD | 19.56% |
| 2018 Q3 | 957 Thousand USD | -4.78% |
| 2018 Q2 | 1 Million USD | 8.18% |
| 2018 FY | 1.11 Million USD | 41.21% |
| 2018 Q1 | 929 Thousand USD | 17.45% |
| 2018 Q4 | 1.11 Million USD | 16.72% |
| 2017 Q2 | 576 Thousand USD | -71.47% |
| 2017 Q1 | 2.01 Million USD | -48.96% |
| 2017 FY | 791 Thousand USD | -80.01% |
| 2017 Q4 | 791 Thousand USD | 3.13% |
| 2017 Q3 | 767 Thousand USD | 33.16% |
| 2016 FY | 3.95 Million USD | 322.01% |
| 2016 Q4 | 3.95 Million USD | -2.68% |
| 2016 Q1 | 900 Thousand USD | -3.99% |
| 2016 Q3 | 4.06 Million USD | 400.0% |
| 2016 Q2 | 813 Thousand USD | -9.67% |
| 2015 Q2 | 692.2 Thousand USD | 12.33% |
| 2015 Q3 | 481.22 Thousand USD | -30.48% |
| 2015 Q4 | 937.41 Thousand USD | 94.79% |
| 2015 FY | 937.41 Thousand USD | 66.81% |
| 2015 Q1 | 616.22 Thousand USD | 9.65% |
| 2014 FY | 561.97 Thousand USD | 90.56% |
| 2014 Q4 | 561.97 Thousand USD | 98.47% |
| 2014 Q3 | 283.15 Thousand USD | -15.1% |
| 2014 Q2 | 333.51 Thousand USD | -20.58% |
| 2014 Q1 | 419.95 Thousand USD | 42.41% |
| 2013 Q3 | 173.75 Thousand USD | -35.13% |
| 2013 Q1 | 290.41 Thousand USD | -11.79% |
| 2013 Q2 | 267.85 Thousand USD | -7.77% |
| 2013 FY | 294.89 Thousand USD | -10.43% |
| 2013 Q4 | 294.89 Thousand USD | 69.72% |
| 2012 Q3 | 268.57 Thousand USD | 10.51% |
| 2012 Q1 | 246.59 Thousand USD | -22.0% |
| 2012 Q2 | 243.02 Thousand USD | -1.45% |
| 2012 Q4 | 329.24 Thousand USD | 22.59% |
| 2012 FY | 329.24 Thousand USD | 4.15% |
| 2011 Q2 | 220.72 Thousand USD | 17.46% |
| 2011 FY | 316.13 Thousand USD | 28.11% |
| 2011 Q4 | 316.13 Thousand USD | 54.21% |
| 2011 Q3 | 204.99 Thousand USD | -7.12% |
| 2011 Q1 | 187.9 Thousand USD | -23.85% |
| 2010 FY | 246.75 Thousand USD | -6.85% |
| 2010 Q1 | 335.88 Thousand USD | 26.8% |
| 2010 Q2 | 412.84 Thousand USD | 22.91% |
| 2010 Q3 | 72.05 Thousand USD | -82.55% |
| 2010 Q4 | 246.75 Thousand USD | 242.47% |
| 2009 Q3 | 246.83 Thousand USD | 7.28% |
| 2009 Q4 | 264.9 Thousand USD | 7.32% |
| 2009 Q2 | 230.08 Thousand USD | -13.04% |
| 2009 Q1 | 264.58 Thousand USD | -19.16% |
| 2009 FY | 264.9 Thousand USD | -19.06% |
| 2008 Q4 | 327.28 Thousand USD | 19735.45% |
| 2008 FY | 327.28 Thousand USD | 72.65% |
| 2008 Q1 | 14.75 Thousand USD | -95.51% |
| 2008 Q2 | 7305.00 USD | -50.47% |
| 2008 Q3 | 1650.00 USD | -77.41% |
| 2007 FY | 189.56 Thousand USD | -18.25% |
| 2007 Q4 | 328.47 Thousand USD | 57.6% |
| 2007 Q2 | 189.56 Thousand USD | -1.74% |
| 2007 Q1 | 192.92 Thousand USD | -32.03% |
| 2007 Q3 | 208.41 Thousand USD | 9.95% |
| 2006 Q1 | 161.92 Thousand USD | 15.62% |
| 2006 Q3 | 250.54 Thousand USD | 8.05% |
| 2006 Q4 | 283.85 Thousand USD | 13.29% |
| 2006 FY | 231.87 Thousand USD | -27.31% |
| 2006 Q2 | 231.87 Thousand USD | 43.2% |
| 2005 Q2 | 318.97 Thousand USD | 0.0% |
| 2005 Q3 | 146.47 Thousand USD | -54.08% |
| 2005 Q4 | 140.05 Thousand USD | -4.38% |
| 2005 FY | 318.97 Thousand USD | 31.6% |
| 2004 FY | 242.37 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | 42.404% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -16.961% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 92.861% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 97.905% |
| Better Therapeutics, Inc. | 23.84 Million USD | 88.344% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 66.453% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 72.138% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 89.449% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 91.256% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 95.998% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 65.025% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 94.224% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 98.234% |
| Innovation1 Biotech Inc. | 3.5 Million USD | 20.735% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 86.947% |
| Molecular Templates, Inc. | 31.17 Million USD | 91.085% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 77.794% |
| NexImmune, Inc. | 5.08 Million USD | 45.341% |
| Orgenesis Inc. | 35.53 Million USD | 92.18% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 83.17% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -943.113% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -21.072% |
| Scopus BioPharma Inc. | 7.45 Million USD | 62.72% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 99.438% |
| Statera Biopharma, Inc. | 22.67 Million USD | 87.745% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 74.537% |
| Trevena, Inc. | 48.26 Million USD | 94.242% |
| Vaxxinity, Inc. | 30.94 Million USD | 91.019% |
| Vaccinex, Inc. | 5.94 Million USD | 53.231% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -41.185% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 92.758% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -0.632% |